Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease
Le Guen Y, Belloy ME, Grenier-Boley B, de Rojas I, Castillo-Morales A, Jansen I, Nicolas A, Bellenguez C et al.. JAMA neurology, 2022-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To determine whether rare missense variants on APOE are associated with AD risk. Main outcomes and measures In primary analyses, the AD risk associated with each missense variant was estimated, as appropriate, with either linear mixed-model regression or logistic regression. Results A total of 544 384 participants were analyzed in the primary case-control analysis; 312 476 (57.4%) were female, and the mean (SD; range) age was 64.9 (15.2; 40-110) years. Two missense variants were associated with a 2-fold to 3-fold decreased AD risk: APOE ε4 (R251G) (odds ratio, 0.44; 95% CI, 0.33-0.59; P = 4.7 × 10-8) and APOE ε3 (V236E) (odds ratio, 0.37; 95% CI, 0.25-0.56; P = 1.9 × 10-6). Additionally, the cumulative incidence of AD in carriers of these variants was found to grow more slowly with age compared with noncarriers. Conclusions and relevance In this genetic association study, a novel variant associated with AD was identified: R251G always coinherited with ε4 on the APOE gene, which mitigates the ε4-associated AD risk. The large risk reductions reported here suggest that protein chemistry and functional assays of these variants should be pursued, as they have the potential to guide drug development targeting APOE.
What this study adds
Evidence grade: Moderate
This is a case-control study of 37 participants. In this large genetic study, two rare APOE variants were linked to a 2-fold to 3-fold lower risk of Alzheimer disease, and carriers developed the disease more slowly with age. Reported effect size: 57.4%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Le Guen, Y., Belloy, M. E., Grenier-Boley, B., de Rojas, I., Castillo-Morales, A., Jansen, I., et al. (2022). Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA neurology. https://doi.org/10.1001/jamaneurol.2022.1166
Vancouver
Le Guen Y, Belloy ME, Grenier-Boley B, de Rojas I, Castillo-Morales A, Jansen I, et al. Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA neurology. 2022. doi:10.1001/jamaneurol.2022.1166. PMID: 35639372.
BibTeX
@article{leguen2022-35639372,
author = {Le Guen, Y. and Belloy, M. E. and Grenier-Boley, B. and de Rojas, I. and Castillo-Morales, A. and Jansen, I. and Nicolas, A. and Bellenguez, C. and others},
title = {{Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease}},
journal = {JAMA neurology},
year = {2022},
doi = {10.1001/jamaneurol.2022.1166},
pmid = {35639372},
url = {https://doi.org/10.1001/jamaneurol.2022.1166}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Objective To determine whether rare missense variants on APOE are associated with AD risk.
- Main outcomes and measures In primary analyses, the AD risk associated with each missense variant was estimated, as appropriate, with either linear mixed-model regression or logistic regression.
- Results A total of 544 384 participants were analyzed in the primary case-control analysis; 312 476 (57.4%) were female, and the mean (SD; range) age was 64.9 (15.2; 40-110) years.
- Two missense variants were associated with a 2-fold to 3-fold decreased AD risk: APOE ε4 (R251G) (odds ratio, 0.44; 95% CI, 0.33-0.59; P = 4.7 × 10-8) and APOE ε3 (V236E) (odds ratio, 0.37; 95% CI, 0.25-0.56; P = 1.9 × 10-6).
- Additionally, the cumulative incidence of AD in carriers of these variants was found to grow more slowly with age compared with noncarriers.
Why it matters
In this large genetic study, two rare APOE variants were linked to a 2-fold to 3-fold lower risk of Alzheimer disease, and carriers developed the disease more slowly with age. The authors say these findings could help guide drug development targeting APOE, but no treatment has yet been tested or shown to work.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcase-control study
- Participants37
- Effect size57.4%
- Evidence strengthModerate
How this study scored 67/100
Published in a leading specialty journal, and it is a case-control study. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 37 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 93 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 15.5 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 4 / 6 | Cited 9.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 11 other studies in this library |
| Still being cited | 3 / 4 | Cited 70 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Pablo Mir: h-index 59 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 126 institution(s) in 19 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35639372) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2022.1166
- PubMed: 35639372
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Genetics from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.